KeratOPrinter
Develops a 4D bioprinting suite to produce biocompatible, full-thickness human corneas using iPSC-derived cells to address the global shortage of donor corneas.
- CEO / Founder
- Heli Skottman
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- $8.7M
- Latest Round
- Grant
- Key Investors
- European Union; Horizon Europe
Technology & Products
Key Products
4D Bioprinting Suite; iPSC-derived corneal cells; Bioinks; Portable incubators
Technological Advantage
(1) Claimed: Scalable GMP production of biocompatible corneas using 4D bioprinting. (2) Verified: €8M Horizon Europe grant approval and consortium of 9 specialized partners.
Differentiation
Value Proposition
Provides a sustainable, scalable alternative to donor corneas by producing functional grafts via 4D bioprinting, potentially reducing long-term costs associated with donor procurement and transplant waitlists.
How They Differentiate
Differentiates by focusing on full-thickness corneal grafts using 4D bioprinting and iPSC technology, whereas existing solutions often focus on partial layers or non-biological synthetic materials.
Market & Competition
Target Customers
Clinicians and hospitals specializing in corneal transplantation
Industry Verticals
Ophthalmology; Regenerative Medicine
Competitors
Precise Bio; Pandorum Technologies; LinkoCare Life Sciences
Growth & Milestones
Growth Metrics
Aims for scalable GMP production to treat millions; €8M grant funding secured for development.
Major Milestones
Horizon Europe grant approval; Consortium assembly; Project launch; Targeting pilot transplants in 3-5 years; Clinical availability targeted by 2035
Notable Customers
Tampere University; StemSight Oy; Brinter AM Technologies Oy; Maastricht University; University Hospital Cologne (Klinikum der Universität zu Köln); University of Helsinki; Cellbox Solutions; Asphalion SL; Crowdhelix Limited